| Working Paper |
File Downloads |
Abstract Views |
| Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
| A Taste of Their Own Medicine: Guideline Adherence and Access to Expertise |
0 |
0 |
0 |
21 |
1 |
3 |
6 |
41 |
| Adverse Selection in Insurance Markets: Policyholder Evidence from the U.K. Annuity Market |
0 |
0 |
0 |
451 |
1 |
3 |
14 |
1,693 |
| Approaches to Estimating the Health State Dependence of the Utility Function |
0 |
0 |
0 |
34 |
0 |
2 |
12 |
120 |
| Approaches to Estimating the Health State Dependence of the Utility Function |
0 |
0 |
0 |
73 |
0 |
4 |
13 |
198 |
| Beyond Statistics: The Economic Content of Risk Scores |
0 |
0 |
0 |
30 |
0 |
1 |
8 |
67 |
| Beyond Testing: Empirical Models of Insurance Markets |
0 |
0 |
0 |
91 |
1 |
7 |
23 |
286 |
| Beyond Testing: Empirical Models of Insurance Markets |
0 |
0 |
0 |
15 |
2 |
4 |
13 |
109 |
| Bunching at the Kink: Implications for Spending Responses to Health Insurance Contracts |
0 |
0 |
0 |
38 |
1 |
4 |
8 |
90 |
| Clinician Behavior When Skin-Tone Affects Test Results |
0 |
0 |
13 |
13 |
3 |
4 |
33 |
33 |
| Did Medicare Induce Pharmaceutical Innovation? |
0 |
0 |
0 |
140 |
1 |
7 |
16 |
675 |
| Did Medicare Induce Pharmaceutical Innovation? |
0 |
0 |
0 |
4 |
1 |
4 |
18 |
168 |
| Dynamic Inefficiencies in Insurance Markets: Evidence from long-term care insurance |
0 |
0 |
0 |
111 |
0 |
3 |
9 |
515 |
| E-ZTax: Tax Salience and Tax Rates |
1 |
1 |
1 |
57 |
3 |
7 |
24 |
312 |
| Empirical Analyses of Selection and Welfare in Insurance Markets: A Self-Indulgent Survey |
1 |
1 |
1 |
8 |
2 |
6 |
21 |
46 |
| Estimating Welfare in Insurance Markets Using Variation in Prices |
0 |
0 |
0 |
62 |
0 |
1 |
14 |
278 |
| Estimating Welfare in Insurance Markets Using Variation in Prices |
0 |
0 |
1 |
24 |
1 |
2 |
12 |
151 |
| Estimating Welfare in Insurance Markets Using Variation in Prices |
0 |
0 |
0 |
14 |
0 |
5 |
18 |
127 |
| Geographic Variation in Healthcare Utilization: The Role of Physicians |
0 |
0 |
0 |
34 |
2 |
10 |
34 |
82 |
| Health Policy and Technological Change: Evidence from the Vaccine Industry |
0 |
0 |
2 |
135 |
1 |
4 |
15 |
599 |
| Healthcare Exceptionalism? Performance and Allocation in the U.S. Healthcare Sector |
0 |
0 |
1 |
37 |
0 |
7 |
31 |
127 |
| Healthcare Exceptionalism? Productivity and Allocation in the U.S. Healthcare Sector |
0 |
0 |
0 |
44 |
1 |
4 |
14 |
207 |
| Healthcare Spending and Utilization in Public and Private Medicare |
0 |
0 |
0 |
61 |
1 |
8 |
37 |
136 |
| Heterogeneity in Damages from A Pandemic |
0 |
0 |
0 |
16 |
1 |
3 |
10 |
33 |
| How General Are Risk Preferences? Choices Under Uncertainty in Different Domains |
0 |
0 |
0 |
41 |
2 |
5 |
16 |
259 |
| How general are risk preferences? Choices under uncertainty in different domains |
0 |
0 |
0 |
52 |
2 |
3 |
13 |
231 |
| In Praise of Moderation: Suggestions for the Scope and Use of Pre-Analysis Plans for RCTs in Economics |
0 |
0 |
2 |
74 |
3 |
8 |
25 |
235 |
| Income and Health Spending: Evidence from Oil Price Shocks |
0 |
0 |
0 |
88 |
0 |
4 |
22 |
376 |
| Income and Health Spending: Evidence from Oil Price Shocks |
0 |
0 |
0 |
200 |
1 |
1 |
12 |
567 |
| Input and Technology Choices in Regulated Industries: Evidence From the Health Care Sector |
0 |
1 |
1 |
121 |
2 |
11 |
24 |
617 |
| Insuring Long Term Care In the US |
0 |
0 |
0 |
80 |
1 |
3 |
9 |
216 |
| Is American Pet Health Care (Also) Uniquely Inefficient? |
0 |
0 |
0 |
21 |
1 |
5 |
21 |
97 |
| Lives vs. Livelihoods: The Impact of the Great Recession on Mortality and Welfare |
0 |
0 |
1 |
28 |
4 |
24 |
48 |
111 |
| Long-Term Care Hospitals: A Case Study in Waste |
0 |
0 |
0 |
31 |
0 |
2 |
10 |
105 |
| Market Design in Regulated Health Insurance Markets: Risk Adjustment vs. Subsidies |
0 |
0 |
1 |
8 |
1 |
2 |
16 |
36 |
| Medicaid Crowd-Out of Private Long-Term Care Insurance Demand: Evidence from the Health and Retirement Survey |
0 |
0 |
0 |
98 |
1 |
2 |
7 |
581 |
| Medicare Home Health Fraud: How Much, Where, and Who? |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Minimum Standards and Insurance Regulation: Evidence from the Medigap Market |
0 |
0 |
0 |
74 |
0 |
2 |
8 |
446 |
| Moral Hazard in Health Insurance: How Important Is Forward Looking Behavior? |
0 |
2 |
2 |
50 |
1 |
8 |
18 |
314 |
| Moral Hazard in Health Insurance: What We Know and How We Know It |
0 |
2 |
3 |
55 |
7 |
27 |
58 |
215 |
| Moral hazard in health insurance: How important is forward looking behavior? |
0 |
0 |
0 |
32 |
0 |
3 |
12 |
250 |
| On the Optimality of Deferred Public Annuities |
0 |
0 |
5 |
5 |
3 |
6 |
16 |
16 |
| Out of the Woodwork: Enrollment Spillovers in the Oregon Health Insurance Experiment |
0 |
0 |
0 |
7 |
0 |
2 |
12 |
36 |
| Overlapping Policy Interventions: Evidence from Home Health |
0 |
0 |
12 |
12 |
1 |
2 |
14 |
14 |
| Paternalistic Social Assistance: Evidence and Implications from Cash vs. In-Kind Transfers |
1 |
1 |
10 |
10 |
1 |
4 |
18 |
18 |
| Paying on the Margin for Medical Care: Evidence from Breast Cancer Treatments |
0 |
0 |
0 |
30 |
0 |
2 |
22 |
79 |
| Paying on the margin for medical care: Evidence from breast cancer treatments |
0 |
0 |
0 |
22 |
0 |
3 |
8 |
53 |
| Place-Based Drivers of Mortality: Evidence from Migration |
0 |
0 |
1 |
56 |
0 |
4 |
16 |
124 |
| Preference Heterogeneity and Insurance Markets: Explaining a Puzzle of Insurance |
0 |
0 |
0 |
137 |
0 |
2 |
12 |
423 |
| Preference Heterogeneity and Insurance Markets: Explaining a Puzzle of Insurance |
0 |
0 |
0 |
11 |
0 |
1 |
6 |
113 |
| Private Information and its Effect on Market Equilibrium: New Evidence from Long-Term Care Insurance |
1 |
1 |
2 |
157 |
1 |
1 |
14 |
737 |
| Private Provision of Social Insurance: Drug-specific Price Elasticities and Cost Sharing in Medicare Part D |
0 |
1 |
1 |
29 |
2 |
5 |
24 |
127 |
| Producing Health: Measuring Value Added of Nursing Homes |
0 |
0 |
3 |
27 |
0 |
7 |
21 |
69 |
| Provider Incentives and Healthcare Costs: Evidence from Long-Term Care Hospitals |
0 |
0 |
0 |
37 |
0 |
2 |
10 |
78 |
| Racial Differences in Nursing Home Value Added |
0 |
0 |
2 |
2 |
0 |
3 |
16 |
16 |
| Re-Examining Geographic Variation in Health and Health Care |
0 |
1 |
20 |
20 |
1 |
14 |
28 |
28 |
| Redistribution by Insurance Market Regulation: Analyzing a Ban on Gender-Based Retirement Annuities |
0 |
0 |
0 |
44 |
0 |
4 |
12 |
392 |
| Screening and Selection: The Case of Mammograms |
0 |
0 |
0 |
11 |
0 |
3 |
14 |
75 |
| Selection Effects in the Market for Individual Annuities: New Evidence from the United Kingdom |
0 |
0 |
0 |
203 |
0 |
6 |
9 |
1,517 |
| Selection in Insurance Markets: Theory and Empirics in Pictures |
0 |
0 |
0 |
30 |
1 |
3 |
16 |
194 |
| Selection in Insurance Markets: Theory and Emprirics in Pictures |
0 |
0 |
0 |
24 |
0 |
1 |
12 |
156 |
| Selection on Moral Hazard in Health Insurance |
0 |
0 |
1 |
68 |
0 |
1 |
25 |
215 |
| Selection on Moral Hazard in Health Insurance |
0 |
0 |
0 |
62 |
1 |
6 |
28 |
292 |
| Social Insurance: Connecting Theory to Data |
0 |
0 |
0 |
280 |
2 |
7 |
29 |
834 |
| Sources of Geographic Variation in Health Care: Evidence from Patient Migration |
0 |
0 |
3 |
94 |
0 |
4 |
31 |
245 |
| Subsidizing Health Insurance for Low-Income Adults: Evidence from Massachusetts |
0 |
0 |
0 |
61 |
2 |
6 |
20 |
124 |
| Supply or Demand: Why is the Market for Long-Term Care Insurance So Small? |
0 |
0 |
0 |
288 |
0 |
3 |
16 |
1,287 |
| Take-up and Targeting: Experimental Evidence from SNAP |
0 |
1 |
1 |
20 |
0 |
7 |
18 |
94 |
| Targeting Precision Medicine: Evidence from Prenatal Screening |
0 |
0 |
2 |
20 |
0 |
2 |
12 |
25 |
| Testing for Asymmetric Information Using 'Unused Observables' in Insurance Markets: Evidence from the U.K. Annuity Market |
0 |
0 |
0 |
131 |
1 |
4 |
10 |
561 |
| The Aggregate Effects of Health Insurance: Evidence from the Introduction of Medicare |
2 |
4 |
5 |
179 |
5 |
16 |
37 |
1,032 |
| The Challenges of Universal Health Insurance in Developing Countries: Evidence from a Large-scale Randomized Experiment in Indonesia |
0 |
0 |
0 |
139 |
0 |
1 |
29 |
226 |
| The Economic Consequences of Hospital Admissions |
0 |
0 |
1 |
63 |
0 |
1 |
11 |
157 |
| The Effect of Medicaid on Crime: Evidence from the Oregon Health Insurance Experiment |
0 |
0 |
2 |
16 |
2 |
5 |
12 |
17 |
| The Health Wedge and Labor Market Inequality |
0 |
0 |
0 |
19 |
1 |
4 |
12 |
36 |
| The IO of Selection Markets |
0 |
0 |
1 |
42 |
2 |
6 |
21 |
146 |
| The Impact of Medicaid Expansion on Voter Participation: Evidence from the Oregon Health Insurance Experiment |
0 |
0 |
1 |
61 |
2 |
4 |
16 |
77 |
| The Impact of Medicaid on Labor Force Activity and Program Participation: Evidence from the Oregon Health Insurance Experiment |
0 |
0 |
0 |
57 |
0 |
6 |
20 |
217 |
| The Impact of a Child with Down Syndrome |
0 |
0 |
16 |
16 |
0 |
2 |
72 |
72 |
| The Interaction of Partial Public Insurance Programs and Residual Private Insurance Markets: Evidence from the U.S. Medicare Program |
0 |
0 |
0 |
103 |
0 |
7 |
12 |
527 |
| The Interaction of Public and Private Insurance: Medicaid and the Long-Term Care Insurance Market |
0 |
0 |
1 |
169 |
3 |
4 |
23 |
779 |
| The Oregon Health Insurance Experiment: Evidence from the First Year |
0 |
0 |
1 |
66 |
3 |
9 |
38 |
289 |
| The Oregon Health Insurance Experiment: Evidence from the First Year |
1 |
1 |
5 |
161 |
2 |
17 |
56 |
679 |
| The RAND Health Insurance Experiment, Three Decades Later |
0 |
1 |
2 |
85 |
4 |
11 |
27 |
403 |
| The RAND Health Insurance Experiment, Three Decades Later |
0 |
0 |
1 |
29 |
1 |
5 |
23 |
203 |
| The Response of Drug Expenditures to Non-Linear Contract Design: Evidence from Medicare Part D |
0 |
0 |
2 |
14 |
0 |
2 |
11 |
96 |
| The Value of Medicaid: Interpreting Results from the Oregon Health Insurance Experiment |
0 |
0 |
0 |
75 |
2 |
4 |
18 |
147 |
| The Welfare Cost of Asymmetric Information: Evidence from the U.K. Annuity Market |
0 |
0 |
0 |
81 |
0 |
7 |
28 |
428 |
| Trading Goods for Lives: NAFTA’s Mortality Impacts and Implications |
0 |
9 |
9 |
9 |
3 |
33 |
34 |
34 |
| Voluntary Regulation: Evidence from Medicare Payment Reform |
0 |
0 |
0 |
11 |
0 |
2 |
11 |
56 |
| Welfare Analysis Meets Causal Inference |
0 |
0 |
0 |
16 |
1 |
5 |
18 |
80 |
| What Did Medicare Do (And Was It Worth It)? |
0 |
0 |
1 |
141 |
2 |
7 |
19 |
714 |
| What Does (Formal) Health Insurance Do, and For Whom? |
0 |
0 |
0 |
48 |
0 |
3 |
13 |
72 |
| What Drives Risky Prescription Opioid Use? Evidence from Migration |
0 |
0 |
2 |
57 |
1 |
8 |
33 |
171 |
| What Good Is Wealth Without Health? The Effect of Health on the Marginal Utility of Consumption |
2 |
2 |
4 |
93 |
7 |
18 |
31 |
398 |
| What Good Is Wealth without Health? The Effect of Health on the Marginal Utility of Consumption |
0 |
0 |
0 |
98 |
1 |
5 |
18 |
317 |
| When Can Partial Public Insurance Produce Pareto Improvements? |
0 |
0 |
0 |
112 |
0 |
5 |
9 |
480 |
| Why is End-of-Life Spending So High? Evidence from Cancer Patients |
0 |
0 |
0 |
17 |
0 |
2 |
8 |
57 |
| Total Working Papers |
9 |
29 |
146 |
6,441 |
107 |
527 |
1,871 |
26,601 |
LogEc is hosted by the
Örebro University School of Business.